WeVote
Log In

Bill

Bill

S 5580

Requires the commissioner of health to establish and publish a list of generic drug products; repealer

2025 Regular Session Introduced by Andrew Lanza

Requires NY Health Commissioner to publish a public list of generic drugs, replacing current rules and boosting transparency for prescribers, pharmacists, payers, and patients.

REFERRED TO HEALTH
0
WeVote Research Nonpartisan
Bill Summary · S 5580

Summary of S 5580

Bill: S 5580 — Requires the commissioner of health to establish and publish a list of generic drug products; repealer

Status: REFERRED TO HEALTH
Introduced: February 25, 2025
Classification: bill

Sponsor: Andrew J. Lanza (primary)

Related legislation (prior sessions): S 5099, S 6739, S 5471, S 2391, S 5158, S 4181

Purpose and intent

  • The bill would require the New York State Commissioner of Health to establish a list of generic drug products and publish that list for public access.
  • The overarching aim appears to be increased transparency around which generic drug products are available, supporting informed purchasing and prescribing decisions. Details on scope, format, and update frequency would be defined in the bill’s text.

Key provisions (as indicated by title)

  • Establishment of a government-maintained list: The commissioner of health must create a list of generic drug products.
  • Public publication: The list must be published and presumably maintained as a public resource.
  • Repealer: The bill includes repealer language, meaning it would repeal existing statutes or provisions related to the subject of generic drug product listings or public disclosure—specifically identified in the text of the bill.

Note: The exact data fields (e.g., drug name, manufacturer, strength, dosage form), update cadence, access methods, and any exclusions would be specified in the bill’s full text.

Who would be affected

  • State health department operations: Administration of the list and ongoing updates.
  • Healthcare providers and pharmacists: Use of the list to inform prescribing and dispensing decisions.
  • Payers and insurers: Potential reference for formulary decisions and price transparency.
  • Generic drug manufacturers: Inclusion in the list could affect visibility and procurement decisions.
  • General public/patients: Access to a transparent resource about available generic products.

Procedural timeline and process

  • Introduced and referred to the Health committee on February 25, 2025.
  • No further actions listed in the provided information; outcomes will depend on committee review, potential amendments, and eventual floor consideration.

Context and considerations

  • The inclusion of a repealer suggests a consolidation or replacement of existing requirements related to generic drug listings; the precise statutory targets would be evident in the bill text.
  • Potential benefits include improved transparency, better procurement choices, and clarity for patients and providers.
  • Potential administrative considerations include the need for ongoing data maintenance, accuracy, and timely updates by the Department of Health.

Notes

  • This summary reflects the information available in the bill metadata. Full text is needed to detail the exact provisions, data elements, update schedules, and the specific provisions repealed.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.